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Abstract
The aim of this study was to examine the effect of ACS14, a hydrogen sulfide (H2S)-releasing derivative of aspirin (Asp), on
Asp-induced gastric injury. Gastric hemorrhagic lesions were induced by intragastric administration of Asp (200 mg/kg,
suspended in 0.5% carboxymethyl cellulose solutions) in a volume of 1 ml/100 g body weight. ACS14 (1, 5 or 10 mg/kg)
was given 30 min before the Asp administration. The total area of gastric erosions, H2S concentration and oxidative stress in
gastric tissues were measured three hours after administration of Asp. Treatment with Asp (200 mg/kg), but not ACS14
(430 mg/kg, at equimolar doses to 200 mg/kg Asp), for 3 h significantly increased gastric mucosal injury. The damage
caused by Asp was reversed by ACS14 at 1–10 mg/kg in a concentration-dependent manner. ACS14 abrogated Asp-induced
upregulation of COX-2 expression, but had no effect on the reduced PGE2 level. ACS14 reversed the decreased H2S
concentrations and blood flow in the gastric tissue in Asp-treated rats. Moreover, ACS14 attenuated Asp-suppressed
superoxide dismutase-1 (SOD-1) expression and GSH activity, suggesting that ACS14 may stimulate antioxidants in the
gastric tissue. ACS14 also obviously inhibited Asp-induced upregulation of protein expression of oxidases including XOD,
p47phox and p67phox. In conclusion, ACS14 protects Asp induced gastric mucosal injury by inhibiting oxidative stress in the
gastric tissue.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the
most commonly prescribed drugs due to their high efficacy in
reducing of pain, fever, inflammation and protection against stroke
and myocardial infarction [1]. However, their clinical use is
commonly associated with the occurrence of adverse effects at the
level of digestive tract, ranging from dyspeptic symptoms,
gastrointestinal erosions and peptic ulcers to more serious
complications, such as overt bleeding or perforation [2]. Redox
imbalances appear to play a major pathogenic role in aspirin (Asp)
toxicity and gastropathy [3]. To overcome the adverse effects
related to NSAID-induced gastrointestinal toxicity, different
therapeutic strategies have been evaluated [4–6]. This may
include reducing the risk of gastrointestinal damage induced by
NSAIDs and enhancing the protective function of the gastric
mucosa.
Hydrogen sulfide (H2S) is now well recognized to be an
endogenous gaseous mediator. Like nitric oxide, another ‘‘gaso-
transmitter’’, H2S also regulates various physiological functions
[7,8]. It was recently found that H2S produces strong anti-
oxidative [9], anti-apoptotic [10] and anti-inflammatory effects
[11] in different tissue injuries. H2S and H2S-releasing molecules
are able to enhance intracellular antioxidant activities by means of
several mechanisms, including stimulation of glutathione and
induction of the antioxidant and tissue protective protein heme
oxygenase-1 [12–14].
ACS14 is a H2S releasing compound, 2-acetyloxybenzoic acid
4-(3-thioxo-3H-1, 2-dithiol-5-yl) phenyl ester (ACS 14, S-aspirin)
[15,16]. The pharmacological profile of ACS14 was described
recently [15]. It contains a dithiolethione moiety which gradually
releases H2S for a sustained period [17]. In the present study, we
therefore investigated the effect of ACS14 on Asp-induced gastric
mucosal injury by examining whether ACS14 can prevent Asp-
induced redox imbalances in rats.
Methods
Animals
Male Sprague-Dawley rats, 200–240 g, were obtained from the
Animal Center of Xuzhou Medicine College (Xuzhou, China) and
were housed at 22uC in a controlled environment with 12 h of
artificial light per day. They were fasted for 20–24 h before the
experiments but had free access to drinking water. All animal
experiments were conducted in accordance with international
ethical guidelines and the experimental protocols for using rats
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have been reviewed and approved by the Animal Ethics
Committee at Xuzhou Medicine College.
Asp-induced Gastric Mucosal Injury and ACS14
Treatment
Gastric hemorrhagic lesions were induced by intragastric
administration of Asp (200 mg/kg in 0.5% carboxymethyl
cellulose solutions) in a volume of 1 ml/100 g body weight. To
investigate the preventive effect of ACS14 on Asp-induced gastric
mucosal injury, ACS14 synthesized as previously described [15] at
doses of 1, 5 or 10 mg/kg (dissolved in DMSO) was injected
intraperitoneally 30 min before the administration of Asp. Three
hours after administration of Asp, the animals were killed by over-
dose injection of pentobarbital sodium (60 mg/kg i.p.) and
stomachs were harvested for other experiments.
Gastric Damage: Macroscopic Analysis
Both cardia and pylorus of stomach were ligated. 10 ml of 10%
formaldehyde solution was injected into gastric cavity. The whole
stomach was fixed in the same concentration of formaldehyde
solution overnight. On the second day, the stomach was opened
along the greater curvature, washed lightly and flattened on a
piece of cardboard. The total number of gross mucosal lesions per
stomach was counted and each lesion was scored according to the
following scheme: grade1: petechial lesion, grade 2: lesion#2 mm,
grade 3: 2, lesion#4 mm, grade 4: 4, lesion#6mm and grade 5:
lesion greater than 6 mm.
Measurement of H2S Concentration in Plasma and Gastric
Tissue
The method for measurement of H2S concentration was
described in our previous publications [18,19]. Briefly, 75 ml
plasma or gastric mucosal homogenates from each group were
diluted in deionized water (final volume, 500 ml). H2S was trapped
by addition of zinc acetate (1% w/v, 250 ml). Subsequently, N, N-
dimethyl-p-phenylenediamine sulphate (20 mM; 133 ml) in 7.2 M
HCl was added, followed by FeCl3 (30 mM; 133 ml) in 1.2 M HCl.
Thereafter, trichloroacetic acid (10% w/v, 250 ml) was used to
precipitate any protein that might be present in the culture media
and upon centrifugation (10,000 g) absorbance (670 nm) of
aliquots from the resulting supernatant (300 ml) was determined
using a 96 well microplate reader [20].
Determination of PGE2 Levels
Tissue from each rat stomach was removed, weighed
(approximately 0.1 g), and placed in a test tube containing
1 ml of 0.1 M phosphate buffer, pH 7.4, 1 mM EDTA, and
10 mM indomethacin. The tissue was homogenized and
centrifuged for 20 min at 1,000 g at 4uC. Prostaglandin E2
(PGE2) content in supernatant was determined by an enzyme
immunoassay kit following the protocol described by the
manufacturer (Biovol Technologies, China). Results are ex-
pressed as picograms of PGE2 per milligram of protein. Proteins
were determined by using the bicinchoninic acid (BCA) kit
(Beyotime Institute of Biotechnology, China).
Measurement of Malondialdehyde (MDA) Levels and
Glutathione (GSH) Activity in Gastric Tissue
Approximately 0.5 g of gastric tissue from individual rats was
homogenized in 4.5 ml physiological saline and the supernatants
were obtained by centrifugation at 2,000 g for 10 min. The
protein concentration in the gastric mucosal homogenates was
measured by using the bicinchoninic acid (BCA) kit (Beyotime
Institute of Biotechnology, China). MDA levels and GSH
activity in gastric tissue supernatants were measured using the
enzyme-specific activity detection kits (Nanjing Jiancheng
Bioengineering Co., China), according to the manufacturer’s
instructions.
Determination of Gastric Blood Flow
Rats were anesthetized with pentobarbital sodium (60 mg/kg
i.p.) and operated along the mid-line of abdomen to expose the
stomach. Laser Doppler blood flow meter and miniature surface
probes (moorVMS, UK) were used to record the blood flow. The
acquired signal was converted to blood perfusion unit (BPU) and
recorded with a computer. The curve was analyzed with
moorVMS v1.0 software. Only stable signals were included and
calculated. Blood flow was recorded for three times (15 s for each
time) in each rat.
Western Blot Analysis
Gastric samples were lysed in buffer. The protein concentration of
each lysate was determined using the BCA kit according to the
manufacture’s protocol. 7.5%, 10% or 12.5% SDS-polyacrylamide
gels were used depending on the molecular weight of the measured
proteins. After electrophoresis, the polyvinylidene fluoride (PVDF)
membranes were washed in Tris-buffered saline containing 0.1%
Tween-20 (TBST) for 1 h, and then incubated with the relevant
antibodyat 4uCovernight.All antibodies (anti-SOD1antibody, anti-
XOD antibody, anti-COX2 antibody, anti-phosphorylated p22phox
antibody, anti-p47phox antibody, anti-p67phox antibody and anti-
gp91phox antibody) were purchased from Santa Cruz Biotechnology
Inc., Santa Cruz, CA,USA.Membranes were washed three times in
TBST buffer (10 mmol/l Tris, pH 7.5; 150 mmol/l NaCl, 0.05%
Tween-20), followed by incubation with secondary antibody. The
NBT/BCIP western blot analysis system according to the manufac-
turer’s protocolwas used for detection theprotein signals.The results
are the average of four independent experiments.
Statistical Analysis
All data were presented as mean6 SEM. Statistical significance
was assessed with one-way analysis of variance (ANOVA) followed
by a post hoc (Bonferroni) test for multiple group comparison.
Differences with p-value less than 0.05 were considered statistically
significant.
Results
Effect of ACS14 and Asp on Gastric Mucosa
We first compared the effect of ACS14 and Asp on gastric
mucosa. We found that intragastric administration of ACS14 at
430 mg/kg (at equimolar doses to 200 mg/kg Asp) did not cause
any damage in the gastric mucosa. However, Asp at 200 mg/kg
induced severe mucosal damage. These data suggest that H2S
released from ACS14 may protect against Asp-induced gastric
damage (Fig. 1).
Effect of ACS14 and NaHS on Asp-induced Gastric
Mucosal Injury
Treatment of rats with Asp (200 mg/kg) for 3 h significantly
increased gastric mucosal injury. As shown in Fig. 2, Asp induced
the appearance of multiple visible gastric petechial erosions. The
size of erosions ranged from 2 to 10 mm in length and about
1 mm in width. This damage was reversed by ACS14 at 1–
10 mg/kg in a concentration-dependent manner. The significant
effect was observed when ACS14 was at 5–10 mg/kg. NaHS (an
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H2S donor) at 0.73 mg/kg (produced H2S approximately equiv-
alent to that caused by ACS14 at 5 mg/kg) also decreased the
gastric mucosal injury induced by Asp to a similar extent caused
by ACS14 at 5 mg/kg. These data imply that ACS14 may protect
gastric mucosa against Asp-induced mucosal injury via releasing
H2S.
ACS14 and NaHS Increased H2S Concentrations in Plasma
and Gastric Tissue
Rats treated with Asp didn’t affect the H2S concentrations in
plasma. Treatment with ACS14 (5 and 10 mg/kg) and NaHS
(0.73 mg/kg) significantly increased the H2S concentrations in
plasma (Fig. 3A). Interestingly, Asp treatment significantly
decreased the local H2S concentration in gastric tissue. This
effect was reversed by ACS14 pretreatment at 10 mg/kg.
(Fig. 3B).
Effect of ACS14 and NaHS on Gastric Blood Flow
Since H2S may dilate blood vessel, we therefore examined the
effect of ACS14 on gastric blood flow. As shown in Fig. 3C, Asp
significantly decreased gastric blood flow. This effect was reversed
by ACS14 at 10 mg/kg. ACS14 at 1 mg/kg, 5 mg/kg and NaHS
at 0.73 mg/kg failed to significantly change the gastric blood flow.
Effects of ACS14 on COX-2 Expression and PGE2 Content
in Gastric Tissue
Cyclooxygenase 2 (COX-2) is an inducible enzyme that
participates in inflammation by producing prostanoids including
PGE2. COX-2 expression was significantly increased in the gastric
tissue after treatment with Asp (Fig. 4A). Pretreatment with
ACS14 at 5–10 mg/kg and NaHS at 0.73 mg/kg reversed the up-
regulated expression of COX-2, suggesting that the protective
effects may be mediated by suppression of COX-2 expression.
However, the PGE2 level was markedly reduced in rats treated
Figure 1. Effect of Asp at 200 mg/kg and ACS14 (430mg/kg) on the morphology of gastric mucosa in rats. ACS14 or Asp was
administered to rats 3 h by intragastric administration. Representative photographs (A) and group data (B) showing that Asp, but not ACS14, induced
significant gastric mucosal injury. Data are presented as means 6 SE. n = 6. * P,0.05 compared with control; # P,0.05 compared with Asp.
doi:10.1371/journal.pone.0046301.g001
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Figure 2. Effect of ACS14 on Asp-induced gastric mucosal injury in rats. ACS14 (1, 5 or 10 mg/kg) was given (i.p.) 30 min before intragastric
administration of Asp (200 mg/kg). Representative photographs (A) and group data (B) showing ACS14 significantly attenuated Asp-induced gastric
mucosal injury. Data are presented as means 6 SE. n = 8. *P,0.05 compared with control; #P,0.05 compared with Asp; {P,0.05 compared with
Asp+ACS14 1 mg/kg.
doi:10.1371/journal.pone.0046301.g002
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with Asp (200 mg/kg). This effect was not rescued by treatment
with either ACS14 or NaHS (Fig. 4B).
ACS14 and NaHS Decreased Asp-induced Gastric
Oxidative Stress
It is well known that Asp-induced gastric injury is caused by
oxidative stress [3,21]. We therefore examined the levels of gastric
MDA, one of the markers of free radical species-related injury. As
expected, the levels of gastric MDA were significantly elevated in
Asp group of rats, as compared with the control group (Fig. 5A,
P,0.05). Pretreatment with ACS14 at 10 mg/kg obviously
reduced the elevated MDA level. Treatment with NaHS
(0.73 mg/kg) showed a trend of decreasing gastric MDA when
compared with Asp alone group, but no significant difference was
found. The results suggest that ACS14 appeared to be a potent
antioxidant regulator to attenuate the Asp-induced gastric injury
in rats.
GSH is the most important antioxidant. As shown in Fig. 5B,
Asp markedly suppressed intracellular GSH production from
10.2760.54 mmol/g protein to 7.5961.54 mmol/g protein. This is
consistent with the previous findings [22]. Pretreatment with
ACS14 at 5 and 10 mg/kg significantly increased the gastric GSH
level.
SOD-1 is one of three superoxide dismutases responsible for
destroying free superoxide radicals in the body. As shown in
Fig. 5C, Asp treatment significantly decreased the expression of
SOD-1 in the gastric tissue. Similarly, pretreatment with ACS14
and NaHS reversed the down-regulation of SOD-1 expression
induced by Asp.
Xanthine oxidase (XOD) is an oxidase which produces reactive
oxygen species. XOD expression in gastric tissue was significantly
increased by Asp treatment (Fig. 5D). Treatment with ACS14 and
NaHS suppressed Asp-induced upregulation of XOD expression.
The NADPH oxidase is a membrane-bound enzyme complex.
It generates superoxide by transferring electrons from NADPH to
molecular oxygen to produce the superoxide. NADPH comprises
p22phox, gp91phox, p40phox, p47phox, p67phox, and the small GTP-
binding protein Rac [23–25]. As shown in Fig. 6, Asp significantly
upregulated the protein expression of p22phox (Fig. 6A), p47phox
(Fig. 6B) and p67phox (Fig. 6C), pretreatment with ACS14 and
NaHS significantly attenuated the expression of p47phox and
p67phox, but enhanced the expression of p22phox. However, all the
three drugs, Asp, ACS14 and NaHS had no significant effect on
gp91phox (Fig. 6D).
Discussion
Asp is widely used as an anti-inflammatory and analgesic drug.
However, Asp at therapeutic dose for pain-relief often induces
gastrointestinal adverse effects including gastric ulcer and bleed-
ing. At low doses, Asp is also used to prevent cardiovascular and
cerebrovascular disease [26,27]. The recent clinical studies showed
that even at low dose to prevent cardiovascular disease. Asp also
induces gastroduodenal complications [28–31]. The annoying
adverse effect may largely limit the clinical uses of NSAIDs.
Therefore, development of new salicylate drugs which may not
produce gastrointestinal toxicity is necessary and urgent.
Figure 3. Effect of ACS14 on H2S concentration and basal
gastric mucosal blood flow in rats. A & B. ACS14 increased H2S
concentrations in both blood plasma (A) and gastric tissues (B). n = 7. C.
ACS14 increased basal gastric mucosal blood flow in rats. n = 8. Data are
the means6SE. *P,0.05 compared with control; #P,0.05 compared
with Asp; {P,0.05 compared with Asp+ACS14 1 mg/kg.
doi:10.1371/journal.pone.0046301.g003
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H2S is increasingly being recognized as a fundamental signaling
molecule, and many H2S-releasing compounds were developed in
recent years [15,32–34], such as H2S-releasing naproxen and H2S-
releasing Asp. It has recently been found that NaHS significantly
attenuated the gastric damage caused by Asp [31]. This prompted
us to investigate whether H2S releasing Asp can still produce
gastric injury. ACS14 is a developed H2S-releasing Asp. We found
in the present study that ASC14 at the same dose as Asp failed to
produce gastric injury, suggesting that H2S released from ACS14
may protect stomach against Asp-induced injury.
We then moved on to study whether ACS14 at low doses can
prevent harmful effect of Asp in stomach. We found that ACS14 at
1–10 mg/kg reversed Asp induced gastric damage in a concen-
tration-dependent manner. ACS14 is known to release H2S in
vitro and in vivo [15,35,36]. We also found in the present study
that ACS14 (at 5 and 10 mg/kg) significantly increased the H2S
concentrations in plasma. These data confirmed that the beneficial
effect was from the released H2S from ACS14.
COX is the rate-limiting enzyme to regulate the synthesis of
prostaglandins by conversion of arachidonic acid to PGH2, the
common precursor of bioactive prostaglandins. Two distinct COX
isoforms were reported. COX-1 is responsible for constitutive
prostaglandin formation, whereas COX-2 is usually induced in
response to stress [37]. It was reported that Asp can rapidly up-
regulate COX-2 expression in the stomach [38–40]. We found in
the present study that ACS14 at 1–10 mg/kg reversed the up-
regulated expression of COX-2, in a dose-dependent manner.
This is consistent with a previous study that H2S significantly
attenuated Asp-induced upregulation of COX-2 mRNA level
[39].
Endogenous PGE2 derived from COX-2 is closely related to the
recovery of gastric mucosal injury [41,42] and plays an important
role for the maintenance of gastric mucosal integrity by preventing
exogenous injury to the stomach and accelerating gastric mucosal
healing [43]. It was found in the present study that Asp markedly
decreased PGE2 production. We therefore proposed that the
upregulated COX-2 produce level was secondary to a compen-
satory response to inhibition of COX-2 activity and gastrin PG
synthesis [38]. However, we found that neither ACS14 nor NaHS
reversed Asp-impaired PGE2 production. Our data suggest that
the protective effects of ACS14 and NaHS were not mediated by
PGE2.
Oxidative stress is associated with increased production of
oxidizing species or a significant decrease in the capability of
antioxidant defenses [44]. H2S scavenges oxygen-derived free
radicals [9,45–49], which mediates the protective effects of NaHS
against the toxicity of H2O2 in cells in vitro and also the ischemia-
reperfusion-induced gastric mucosal damage in rats in vivo
[47,50]. We found in the present study that ACS14 significantly
reduced Asp-induced elevation of MDA, one of the markers of free
radical species-related injury. Glutathione is the major cellular
antioxidant and plays an important role in antioxidative stress by
H2S [9,35,51–53]. H2S protects neurons from oxidative stress by
increasing the levels of GSH [9,51,54]. We found in the present
study that ACS14 significantly increased the gastric GSH level. In
addition, ACS14 also reversed Asp-reduced protein expression of
SOD, which is responsible for converting superoxide radicals to
molecular oxygen and hydrogen peroxide within cytoplasm and
mitochondria [55]. Our data suggest that ACS14 may protect the
gastric mucosa against Asp-induced damage via upregulation of
antioxidants level.
We also examined the expressions of redox enzymes, NADPH
oxidase. NADPH oxidase is a multicomponent enzyme that
comprises p22phox, gp91phox, p40phox, p47phox, p67phox, and the
small GTP-binding protein Rac [23–25,56]. We found in the
present study that Asp significantly upregulated the protein
expression levels of 22phox, p47phox and p67phox, but not that of
gp91. These data suggest that Asp may activate NADPH oxidase
by stimulating some subunits of the complex. ACS14 at 10 mg/kg
obviously attenuated Asp-induced upregulation of p47phox and
p67phox subunit expression and therefore protected gastric tissue.
Although p22phox expression was further increased by ACS14 and
Figure 4. Effect of ACS14 on COX-2 expression (A) and PGE2
content (B) in gastric tissue. A. Representative Western blots and
group data showing that ACS14 reversed Asp-upregulated COX-2
expression. n = 4. B. Both ACS14 and NaHS failed to change Asp-
suppressed PGE2 level in gastric tissue. n = 7. Data are the means 6
SE.*P,0.05 compared with control; #P,0.05 compared with Asp;
{P,0.05 compared with Asp+ACS14 1 mg/kg; 1P,0.05 compared with
Asp+ACS14 5 mg/kg.
doi:10.1371/journal.pone.0046301.g004
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NaHS, which didn’t influence the protective role on Asp-induced
gastric injury. This is consistent with the previous findings that
NaHS can inhibit NADPH oxidase expression and concomitant
O2.
2 formation [25,57–59].
XOD catalyzes the conversion reactions of hypoxanthine to
xanthine and xanthine to uric acid, the last reaction in the purine
catabolism, with byproduct of toxic superoxide radical. In this
regard, it is a key enzyme between purine and free radical
metabolism [60]. It was reported that XOD is an endogenous
source of ROS and reactive nitrogen species (RNS) that can
induce oxidative stress and inflect tissue injury [61]. Our findings
showed that Asp significant increased XOD protein level in gastric
tissue and this effect was reversed by ACS14. Taken together, our
data clearly demonstrated that ACS14 may protect gastric mucosa
by suppression of oxidative stress.
We also investigated the effect of ACS14 on the gastric blood
flow. It was found that ACS14 obviously increased Asp-reduced
gastric blood flow. This may further contribute to its anti-oxidant
effect as sufficient blood flow and oxygen supply may wash-out/
inhibit Asp-induced O2.
2 production in gastric tissue. The
Figure 5. Effect of ACS14 on levels of MDA (A) and GSH (B) and protein expressions of SOD1 (C) and XOD (D) of gastric tissues in
Asp-treated rats. Data are presented as means6SE. n = 4–8. *P,0.05 compared with control; #P,0.05 compared with Asp; {P,0.05 compared
with Asp+ACS14 1 mg/kg.
doi:10.1371/journal.pone.0046301.g005
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mechanism underlying the ACS14-increased gastric blood flow
may involve opening of KATP channels. This is supported by a
previous study which showed that systemically application of
exogenous H2S increased gastric mucosal blood flow by activation
of KATP channels [50].
In conclusion, we demonstrated in the present study ACS14, an
H2S releasing Asp, protects gastric mucosa against Asp induced
injury via inhibition of oxidative stress and increasing blood flow
locally.
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